Boston Scientific (NYSE:BSX) landed CE Mark approval in the European Union for its Infinion 16 percutaneous lead, designed for use with the company’s Precision Plus spinal cord stimulator system.
BSX’s spinal cord stimulator leads are designed to mask pain signals to the brain by delivering electrical pulses from an implantable pulse generator.
The Infinion system, still fresh from an FDA win, received late last year, is the first 16-contact percutaneous lead on the global market, doubling the previous max of eight stimulating contacts, according to the Natick, Mass.-based med-tech titan.
"We believe that the European launch of the Infinion 16 lead, coupled with increased awareness of pain management treatment alternatives, will allow us reach a wider patient population," neuromodulation division president and senior VP Maulik Nanavaty said in prepared remarks. "Boston Scientific continues its commitment to innovation by offering pain management physicians more choices to help optimize pain relief for their patients."
Boston Scientific Corp. (NYSE:BSX) nearly sold its neurostimulation division to Stryker Corp. (NYSE:SYK) late last year, but the Natick, Mass.-based medical device maker spiked the deal when the bid didn’t rise high enough. The company then doubled down on the pain management division with a $78 million buyout of Intelect Medical Inc., developer of the Guide deep-brain stimulation programming system.
Wright Group wins 510(k) for Prophecy Inbone guides
Wright Medical Group Inc. (NSDQ:WMGI) announced the 510(k) clearance and limited launch of the Prophecy Inbone pre-operative navigation alignment guides for use with the company’s Inbone total ankle replacement systems. Read more
Eden Spine lands FDA clearance for Giza
Eden Spine received 510(k) clearance for its new generation corpectomy device, the GIZA, designed to replace and fuse a collapsed, damaged or unstable vertebral body. Read more
Sorin touts CE Mark for a clutch of cardiac leads
Sorin Group (BIT:SRN) won CE Mark approval and is preparing commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Read more
